ライフサイエンスコーパス: lymph node biopsy

1 potentially more sensitive than conventional lymph node biopsy).

2 osis is established by serologic methods and lymph node biopsy.

3 He underwent an excisional lymph node biopsy.

4 efficacy of axillary dissection and sentinel lymph node biopsy.

5 mpectomy with seed localization and sentinel lymph node biopsy.

6 tinal lymphoma was followed by DLBCL after a lymph node biopsy.

7 vant radiotherapy and the timing of sentinel lymph node biopsy.

8 ery, the patient had undergone a mediastinal lymph node biopsy.

9 is established by serological methods and/or lymph node biopsy.

10 Ci dose of I methylene blue dye for sentinel lymph node biopsies.

11 s were identified on laparoscopic mesenteric lymph nodes biopsies.

12 ft-tissue abscess procedures 48% (34/71) and lymph node biopsies 67% (10/15) (P < 0.01) were most oft

13 We found that in fresh Hodgkin's disease lymph node biopsies, a subset of HRS cells express a sub

14 er EBV-infected B-cell line, isolated from a lymph node biopsy after kidney transplantation, is pheno

15 nt chemotherapy could safely permit sentinel lymph node biopsy alone when the index node has been suc

16 biopsy plus axillary dissection or sentinel-lymph-node biopsy alone.

17 alignant lymphocytes and lymphoma cells from lymph node biopsies and were expressed at significant le

18 eons in a standardized technique of sentinel lymph node biopsy and to educate those same surgeons in

19 nts underwent lymphatic mapping and sentinel lymph node biopsy, and 10 had a positive axillary lymph

20 One patient had a sentinel lymph node biopsy, and 8 patients underwent head/neck im

21 t intraoperative lymphatic mapping, sentinel lymph node biopsy, and inguinal femoral lymphadenectomy.

22 lder underwent wide local excision, sentinel lymph node biopsy, and lymph node dissection.

23 burden, deselection of patients for sentinel lymph node biopsy, and provision of radiotherapy.

24 plications for the potential use of sentinel lymph node biopsy as an alternative to axillary dissecti

25 erum samples) diagnosed serologically and by lymph node biopsy as having TL were studied.

26 Available evidence for the role of sentinel lymph node biopsy as it applies to conjunctival melanoma

27 tudied highly purified CD4 and CD8 TILs from lymph node biopsies at diagnosis in treatment-naive pati

28 to select appropriate patients for sentinel lymph node biopsy based on multiple prognostic factors,

29 notherapy (3600 or 7200 mg/day) underwent 14 lymph node biopsies before and during therapy.

30 the indications and techniques for sentinel-lymph-node biopsy, but also lymph-node sampling, axillar

31 Sentinel lymph node biopsy can be associated with delays in opera

32 Sentinel lymph node biopsy can be performed either before or afte

33 inical trials will evaluate whether sentinel-lymph-node biopsy can be avoided altogether in selected

34 All patients underwent sentinel lymph node biopsy; completion lymphadenectomy was perfor

35 lysis and histological examination of serial lymph node biopsies confirmed depletion of the CD3+ T ce

36 ormalities, and the findings of a subsequent lymph node biopsy confirmed MCD.

37 h an increased number of Ki-67(+) T cells in lymph node biopsies, consistent with an early antiviral

38 bidity and diagnostic delays associated with lymph node biopsy could be avoided if noninvasive imagin

39 Sentinel lymph node biopsy does not appear to have a significant

40 propriate selection of patients for sentinel lymph node biopsy, especially among patients with thin m

41 is review highlights the utility of sentinel lymph node biopsy for melanoma.

42 nts who underwent thyroidectomy and sentinel lymph node biopsy for papillary thyroid cancer were accr

43 Two patients underwent sequential lymph-node biopsies for the assessment of viral burden i

44 or staging has now been replaced by sentinel-lymph-node biopsy for patients with clinically negative

45 Digital images of sentinel lymph node biopsies from 56 patients with small-volume n

46 ocked assay was applied to pretreatment FFPE lymph node biopsies from an independent cohort of 110 pa

47 a variety of sources used as controls, nor 3 lymph node biopsies from patients with B-cell lymphomas,

48 DCs in lymph-node biopsies from the same patients showed a diff

49 approach to patients with positive sentinel lymph node biopsies has increased the complexity of axil

50 Sentinel-lymph-node biopsy has been embraced as a standard of car

51 The introduction of sentinel-lymph-node biopsy has brought new impetus to the early s

52 Sentinel-lymph-node biopsy has spread so rapidly that surgeons, p

53 udies in the past 2 years regarding sentinel lymph node biopsy have been concerned with identifying f

54 Lymphatic mapping and sentinel lymph node biopsy have been established as definitive pr

55 uggested that these new methods for sentinel lymph node biopsy have clinical potential but give high

56 Although details of methods for sentinel lymph node biopsy have yet to be standardised, this tech

57 decision about whether to perform a sentinel lymph node biopsy in 16% of patients (67 of 420 patients

58 r of surgeons capable of performing sentinel lymph node biopsy in a standardized fashion with a high

59 e efficacy of lymphatic mapping and sentinel lymph node biopsy in predicting prognosis, reducing the

60 ic spread undermines the utility of sentinel lymph node biopsy in this condition.

61 It is now well established that sentinel lymph node biopsy is a powerful test to predict prognosi

62 Sentinel lymph node biopsy is a reasonable alternative to inguina

63 An excisional lymph node biopsy is considered the gold standard for di

64 Lymph node biopsy is employed in many cancer surgeries t

65 Sentinel lymph node biopsy is performed as a standard procedure i

66 Sentinel-lymph-node biopsy is associated with increased melanoma-

67 specific PCR identified the same mutation in lymph node biopsy material from patient CEM cells.

68 Absence of lymph node biopsy may result in understaging and inadequ

69 d resistance mutations in blood and inguinal lymph node biopsies obtained from 10 HIV-infected subjec

70 precisely BCL2-IGH translocations present in lymph node biopsies of follicular lymphoma patents.

71 s, it seems reasonable to recommend sentinel lymph node biopsy or at least strict regional lymph node

72 e, it may be reasonable to consider sentinel lymph node biopsy or close nodal surveillance and follow

73 erefore be reasonable to consider a sentinel lymph node biopsy or strict regional lymph node surveill

74 with histologic findings from bone marrow or lymph node biopsy performed within 6 wk of PET/CT and wi

75 ssigned women with breast cancer to sentinel-lymph-node biopsy plus axillary dissection or sentinel-l

76 ctomy (PM), partial mastectomy with sentinel lymph node biopsy (PM SLNB), laparoscopic cholecystectom

77 ymph-node dissection, the role of 'sentinel' lymph-node biopsy, radiobiology and radiotherapy fractio

78 characteristics, trends in usage of sentinel lymph node biopsy, rates of local and distant recurrence

79 Exercise and physical activity and sentinel lymph node biopsy reduce risk, and overweight and obesit

80 techniques could potentially render sentinel lymph node biopsy redundant in the future.

81 of melanoma (16%) after a negative sentinel lymph node biopsy result was similar to that in previous

82 k of recurrence, despite a negative sentinel lymph node biopsy result.

83 We analyzed 46 fresh lymph node biopsy samples, including FL (n = 20), diffus

84 Lymph-node biopsy samples showed that focal lymphadeniti

85 Sentinel lymph node biopsy (SLN) is an accepted alternative to ax

86 There was a higher proportion of sentinel lymph node biopsies (SLNB) performed by high-volume surg

87 Observations: Sentinel lymph node biopsy (SLNB) after NAC in patients presentin

88 ode assessment (ALNA) consisting of sentinel lymph node biopsy (SLNB) alone if sentinel lymph nodes (

89 concerting lymphedema rates in both sentinel lymph node biopsy (SLNB) and axillary lymph node dissect

90 aphy is standardly performed before sentinel lymph node biopsy (SLNB) for breast cancer.

91 Guidelines recommend sentinel lymph node biopsy (SLNB) for patients with clinical stag

92 The validity of sentinel lymph node biopsy (SLNB) for T1 or T2, clinically N0, or

93 Indications for sentinel lymph node biopsy (SLNB) for thin melanoma are continual

94 the sensitivity and specificity of sentinel lymph node biopsy (SLNB) frozen section (FS) examination

95 Sentinel lymph node biopsy (SLNB) has become the gold standard fo

96 entification of nodal metastases by sentinel lymph node biopsy (SLNB) has been questioned.

97 ical setting for the application of sentinel lymph node biopsy (SLNB) in the management of cutaneous

98 Sentinel lymph node biopsy (SLNB) is a newly developed method of

99 Sentinel lymph node biopsy (SLNB) is an accurate, less invasive a

100 Sentinel lymph node biopsy (SLNB) is being evaluated in breast ca

101 inically localized T1 melanoma, yet sentinel lymph node biopsy (SLNB) is controversial in this popula

102 Sentinel lymph node biopsy (SLNB) is currently the standard of ca

103 Sentinel lymph node biopsy (SLNB) is the standard of care for axi

104 800 sec/mm(2)), followed by either sentinel lymph node biopsy (SLNB) or axillary lymph node dissecti

105 nal lymph node evaluation by either sentinel lymph node biopsy (SLNB) or complete lymph node dissecti

106 ith lower- and higher-than-expected sentinel lymph node biopsy (SLNB) positivity rates and whether ho

107 It has been validated that sentinel lymph node biopsy (SLNB) shows whether a patient's breas

108 nce rates of patients who underwent sentinel lymph node biopsy (SLNB) using radiocolloid guidance alo

109 Sentinel lymph node biopsy (SLNB) was developed to replace axilla

110 axillary evaluation, categorized as sentinel lymph node biopsy (SLNB), axillary lymph node dissection

111 pediatric melanoma database, using sentinel lymph node biopsy (SLNB), from 1992 to 2006, identified

112 biopsy results underwent subsequent sentinel lymph node biopsy (SLNB), which yielded negative finding

113 Final pathologic results (sentinel lymph node biopsy [SNB] or axillary lymph node dissectio

114 ences from a Bouin's-fixed paraffin-embedded lymph node biopsy specimen obtained in 1960 from an adul

115 cases), bone marrows (149 cases), and fresh lymph node biopsy specimens (68 cases).

116 4(+) cells was also confirmed by analysis of lymph node biopsy specimens 5 days postchallenge.

117 after the second protein boost, we obtained lymph node biopsy specimens and quantified the frequency

118 al RNA or DNA could be detected in colon and lymph node biopsy specimens collected 13 months after ch

119 oarrays to profile gene expression in serial lymph node biopsy specimens obtained before and after tr

120 xpression of SIV Gag was readily detected in lymph node biopsy specimens taken at 3 weeks postimmuniz

121 With the advent of sentinel lymph node biopsy, surgical methods for accurately stagi

122 Most treatments, including sentinel lymph node biopsy, systemic therapy with taxanes, platin

123 microarrays of paraffin-embedded, diagnostic lymph node biopsies taken from 59 FL patients who lived

124 Refinement of the sentinel-lymph-node biopsy technique might overcome the slightly

125 view to assess three techniques for sentinel lymph node biopsy that are not radioisotope dependent or

126 With the advent of sentinel lymph node biopsy, the axilla can be accurately staged i

127 C), but cultures of BAL fluid and subcarinal lymph node biopsy tissue were negative.

128 ively, in concert with pre- and on-treatment lymph node biopsies to assess retinoblastoma protein (Rb

129 Sentinel lymph node biopsy use and 5-year cumulative incidence of

130 Sentinel lymph node biopsy was adopted for the staging of the axi

131 The absence of lymph node biopsy was also associated with an increased

132 A sentinel lymph node biopsy was performed in 23.3% of the older pa

133 Sentinel lymph node biopsy was performed in 73.7% of white patien

134 Sentinel lymph node biopsy was performed using an increased (99m)

135 Lymph node biopsies were done in two of these three pati

136 ough January 1997, 35 sonographically guided lymph node biopsies were performed in 34 patients.

137 Five hundred consecutive sentinel lymph node biopsies were performed using isosulfan blue

138 patients in whom the diagnosis was based on lymph node biopsy were considered (P =.01).

139 Sentinel lymph node biopsy will not identify metastases in 3% of

140 From 1992 to 2000, we identified 23 lymph node biopsies with focal germinal centers (GCs) co

141 and radiologically normal axilla is sentinel lymph node biopsy with a radioisotope and blue dye (dual

142 ture DC were significantly reduced in day +5 lymph node biopsies, with complete repopulation by 30 da